Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry \[IHC\] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.

Trial Details

NCT ID

NCT06819007

Phase

PHASE3

Sponsor

Daiichi Sankyo

Status

RECRUITING

Cancer Type

Ovarian Cancer

Interventions

Trastuzumab Deruxtecan
Bevacizumab

Locations (sample)

Burbank, California, United States|34.18084,-118.30897
Fort Lauderdale, Florida, United States|26.12231,-80.14338
Miami Beach, Florida, United States|25.79065,-80.13005
Savannah, Georgia, United States|32.08354,-81.09983
Evanston, Illinois, United States|42.04114,-87.69006

Key Eligibility Criteria

Sign and date the tissue prescreening ICF, prior to HER2 central testing. Sign and date the Main ICF, prior to the start of any trial- specific qua…
\*For participants in the safety run-in phase, a safety run-in ICF needs to be signed and dated prior to the start of any trial-specific qualificat…
Adults ≥18 years of age on the day of signing the ICF. Follow local regulatory requirements if the legal age of consent for trial participation is …
Has histologically confirmed diagnosis of epithelial high-grade ovarian, fallopian tube or primary peritoneal carcinoma per local assessment (inclu…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →